688578.SHG Shanghai Allist Pharmaceuticals Co. Ltd. A
- Market cap
- CNY 38.7B
- P/E
- 12.9x
- P/B
- 4.18x
- ROE
- 34.8%
- Dividend yield
- 0.93%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688578.SHG undervalued?
Graham number688578.SHG trades 54.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Allist Pharmaceuticals Co. Ltd. A fundamental analysis
No fundamental analysis for Shanghai Allist Pharmaceuticals Co. Ltd. A yet.
Shanghai Allist Pharmaceuticals Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Allist Pharmaceuticals Co. Ltd. A
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic N…
Full company profileShanghai Allist Pharmaceuticals Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Allist Pharmaceuticals Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 7.73M | 4.62M | 630K | 561K | 530M | 791M | 2.02B | 3.56B | 5.17B | 6.85B |
| Gross Profit | 7.49M | 4.37M | 359K | 399K | 500M | 744M | 1.91B | 3.39B | 5.17B | 6.50B |
| Operating Income | -38.8M | -98.3M | -381M | -310M | 21.8M | 128M | 658M | 1.63B | 2.57B | 3.56B |
| EBITDA | -28.4M | -85.1M | -381M | -297M | 32.7M | 146M | 693M | 1.65B | 2.57B | 3.63B |
| Net Income | -38.9M | -97.4M | -398M | -311M | 18.3M | 131M | 644M | 1.43B | 2.18B | 3.11B |
| EPS | -0.11 | -0.27 | -1.10 | -0.84 | 0.04 | 0.29 | 1.43 | 3.18 | 4.85 | 6.91 |
| Balance Sheet | ||||||||||
| Total Assets | 509M | 375M | 1.33B | 2.99B | 3.13B | 3.44B | 4.38B | 5.92B | 7.90B | 10.1B |
| Total Liabilities | 127M | 304M | 144M | 109M | 157M | 255M | 394M | 633M | -6.50B | 1.11B |
| Shareholders' Equity | 381M | 71.0M | 1.18B | 2.88B | 2.97B | 3.19B | 3.98B | 5.28B | 6.50B | 8.95B |
| Cash & Short-term Investments | 58.9M | 129M | 947M | 2.59B | 2.24B | 2.04B | 2.28B | 3.35B | 3.28B | 1.12B |
| Total Debt | 60.0M | 125M | 110M | 12.2M | 5.39M | 1.96M | 1.82M | 302K | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 10.1M | -97.3M | -259M | -197M | 29.3M | 91.6M | 675M | 1.57B | 2.32B | - |
| Capital Expenditure | 1.40M | 36.0M | 89.4M | 88.5M | 192M | 144M | 67.9M | 270M | 186M | 50.1M |
| Free Cash Flow | 8.72M | -133M | -349M | -285M | -163M | -52.2M | 607M | 1.30B | 2.14B | 3.18B |
| Ratios | ||||||||||
| ROE | -10.2% | -137.1% | -33.6% | -10.8% | 0.6% | 4.1% | 16.2% | 27.1% | 33.6% | 34.8% |
| ROA | -7.7% | -26.0% | -29.9% | -10.4% | 0.6% | 3.8% | 14.7% | 24.2% | 27.6% | 30.9% |
| Net Profit Margin | -503.9% | -2,108.1% | -63,123.4% | -55,361.4% | 3.4% | 16.5% | 31.9% | 40.2% | 42.2% | 45.4% |
| Debt to Equity | 0.16x | 1.76x | 0.09x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai Allist Pharmaceuticals Co. Ltd. A dividends
- Dividend yield
- 0.93%
- Forward dividend
- 1.20 CNY
- Payout ratio
- 16.5%
- Ex-dividend date
- Sep 2, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 360M | 0.80 | 16.5% |
| 2024 | CNY 293M | 0.65 | 20.5% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | CNY 1.19M | 0.00 | - |
| 2019 | CNY 33.4M | 0.09 | - |
| 2018 | 4.50M | 0.01 | - |
| 2017 | 4.26M | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shanghai Allist Pharmaceuticals Co. Ltd. A
- Insiders 53.97%
- Institutions 11.80%
- Public & others 34.22%
- Shares outstanding 450M
- Free float 225M
Shanghai Allist Pharmaceuticals Co. Ltd. A company profile
- Company name
- Shanghai Allist Pharmaceuticals Co. Ltd. A
- Ticker
- 688578.SHG
- ISIN
- CNE100005XJ7
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,989
- Fiscal year end
- December
- Address
- No. 268 Lingxiaohua Road, Shanghai, China, 201318
- Phone
- 86 21 8042 3292
- Website
- allist.com.cn
About Shanghai Allist Pharmaceuticals Co. Ltd. A
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.
Shanghai Allist Pharmaceuticals Co. Ltd. A management
10- Mr. Jinhao DuChairman of the Board & GM · born 1954
- Mr. Jie HuVice Chairman & Deputy GM · born 1975
- Mr. Lin WangFinancial Director · born 1983
- Mr. Chen HuangMarketing Manager · born 1975
- Mr. Feng XuDeputy GM & Director · born 1965
- Ms. Huafeng ShanChief Quality Officer · born 1974
- Ms. Shuo LiBoard Secretary · born 1990
- Quan GanAccounting Supervisor
- Mr. Chang Shou GaoChief Technology Officer · born 1963
- Mr. Huayong ZhouDeputy Director of R&D · born 1984